Literature DB >> 22722677

Current management of patients with severe von Willebrand disease type 3: a 2012 update.

Augusto B Federici1, Paula James.   

Abstract

Von Willebrand disease type 3 (VWD3) is the most severe form of this bleeding disorder due to the almost complete deficiency of von Willebrand factor (VWF). VWD3 is inherited as an autosomal recessive trait. While heterozygous carriers exhibit mild or no bleeding symptoms, most patients with VWD3, which is characterized by undetectable levels of VWF antigen (VWF:Ag) and reduced concentrations (<20 IU/dl) of factor VIII (FVIII), show severe bleeding symptoms. Although the incidence of VWD3 is rare, the condition is of considerable interest because of its severe clinical presentation, the need for replacement therapy and the risk of alloantibodies following infusion of plasma-derived VWF concentrates. This review, based on clinical experience, provides an update on the clinical, laboratory and molecular markers of VWD3 that can be useful for determining the optimal therapeutic approach in these patients.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22722677     DOI: 10.1159/000338208

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  6 in total

1.  G protein-dependent basal and evoked endothelial cell vWF secretion.

Authors:  Luiza Rusu; Alexandra Andreeva; David J Visintine; Kyungho Kim; Stephen M Vogel; Aleksandra Stojanovic-Terpo; Olga Chernaya; Guoquan Liu; Farnaz R Bakhshi; Sandra L Haberichter; Hiroko Iwanari; Osamu Kusano-Arai; Nobuchika Suzuki; Takao Hamakubo; Tohru Kozasa; Jaehyung Cho; Xiaoping Du; Richard D Minshall
Journal:  Blood       Date:  2013-09-30       Impact factor: 22.113

2.  Congenital Type III von Willebrand's disease unmasked by hypothyroidism in a Shetland sheepdog.

Authors:  Margaret Scuderi; Lauren Bessey; Elisabeth Snead; Hilary Burgess; Anthony Carr
Journal:  Can Vet J       Date:  2015-09       Impact factor: 1.008

3.  Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).

Authors:  Guenter Auerswald; Claudia Djambas Khayat; Oleksandra Stasyshyn; Genadi Iosava; Irina Romashevskaya; Marta Julia López; Wilfried Seifert; Tobias Rogosch
Journal:  J Blood Med       Date:  2020-06-22

Review 4.  Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data.

Authors:  Paul Harper; Emmanuel J Favaloro; Julie Curtin; Chris Barnes; Scott Dunkley
Journal:  Drugs Context       Date:  2016-04-08

5.  Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).

Authors:  Toshko J Lissitchkov; Evgeny Buevich; Kazimierz Kuliczkowski; Oleksandra Stasyshyn; Monica Hermida Cerqueira; Anna Klukowska; Christine Joch; Wilfried Seifert
Journal:  Blood Coagul Fibrinolysis       Date:  2017-03       Impact factor: 1.276

6.  Discovery of Type 3 von Willebrand Disease in a Cohort of Patients with Suspected Hemophilia A in Côte d'Ivoire.

Authors:  Adia E Adjambri; Sylvie Bouvier; Roseline N'guessan; Emma N'draman-Donou; Mireille Yayo-Ayé; Marie-France Meledje; Missa L Adjé; Duni Sawadogo
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-03-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.